EyePoint (EYPT) Current Assets (2011 - 2026)
EyePoint (EYPT) posted Current Assets of $249.5 million for Q1 2026, down 24.08% sequentially from $328.7 million in Q4 2025, and down 23.7% YoY from $327.0 million in Q1 2025.
EyePoint (EYPT) Current Assets (2011 - 2026) Analysis & Trends
EyePoint has reported Current Assets for 16 years, with the latest figure at $249.5 million in Q1 2026.
- Quarterly Current Assets fell 23.7% year-over-year to $249.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $249.5 million (down 23.7% YoY) and the FY2025 annual result came in at $328.7 million, down 14.26% from the prior year.
- Current Assets declined to $249.5 million in Q1 2026 per EYPT's latest filing, from $328.7 million in the prior quarter.
- Over five years, Current Assets peaked at $383.3 million in Q4 2024 and troughed at $146.1 million in Q1 2023.
- A 5-year average of $250.0 million and a median of $249.5 million in 2026 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets slumped 33.5% in 2023, then surged 117.52% in 2024.
- Over 5 years, Current Assets stood at $172.8 million in 2022, then surged by 99.53% to $344.8 million in 2023, then grew by 11.17% to $383.3 million in 2024, then decreased by 14.26% to $328.7 million in 2025, then decreased by 24.08% to $249.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $249.5 million, $328.7 million, and $216.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 188.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 188.82 Mn |
| Mar 31, 2026 | 249.50 Mn |
| Dec 31, 2025 | 328.66 Mn |
| Sep 30, 2025 | 216.11 Mn |
| Jun 30, 2025 | 265.25 Mn |
| Mar 31, 2025 | 326.98 Mn |
| Dec 31, 2024 | 383.31 Mn |
| Sep 30, 2024 | 268.55 Mn |
| Jun 30, 2024 | 294.93 Mn |
| Mar 31, 2024 | 317.71 Mn |
| Dec 31, 2023 | 344.80 Mn |
| Sep 30, 2023 | 150.16 Mn |
| Jun 30, 2023 | 167.12 Mn |
| Mar 31, 2023 | 146.06 Mn |
| Dec 31, 2022 | 172.81 Mn |
| Sep 30, 2022 | 192.10 Mn |
| Jun 30, 2022 | 205.87 Mn |
| Mar 31, 2022 | 219.63 Mn |
| Dec 31, 2021 | 237.75 Mn |
| Sep 30, 2021 | 141.78 Mn |